Korean J Gastroenterol.  2023 Apr;81(4):154-162. 10.4166/kjg.2022.113.

Risk of Metabolic Syndrome and Fatty Liver Diseases in Gastric Cancer Survivors: A Propensity Score-Matched Analysis

• Han SJ
• Baik SJ
• Yoon YH
• Kim JH
• Lee HS
• Jeon S
• Park H

• KMID: 2541777
• DOI: http://doi.org/10.4166/kjg.2022.113

Abstract

Background/Aims
To investigate the risk of metabolic syndrome and fatty liver diseases in gastric cancer survivors compared to non-cancer subjects.
Methods
The data from the health screening registry of the Gangnam Severance Hospital from 2014–2019 was used. Ninety-one gastric cancer survivors and a propensity-score-matching 445 non-cancer subjects were analyzed. Gastric cancer survivors were divided into those with surgical treatment (OpGC, n=66) and non-surgical treatment (non-OpGC, n=25). Metabolic syndrome, fatty liver by ultrasonography, and metabolic dysfunction-associated fatty liver disease (MAFLD) were assessed.
Results
Metabolic syndrome was in 15.4% of gastric cancer survivors (OpGC; 13.6%, non-OpGC; 20.0%). Fatty liver by ultrasonography was in 35.2% in gastric cancer survivors (OpGC; 30.3%, non-OpGC: 48.0%). MAFLD was in 27.5% of gastric cancer survivor (OpGC; 21.2%, non-OpGC; 44.0%). After adjusting for age, sex, smoking, and alcohol, the risk of metabolic syndrome was lower in OpGC than in non-cancer subjects (OR, 0.372; 95% CI, 0.176-0.786, p=0.010). After adjusting, OpGC showed lower risks of fatty liver by ultrasonography (OR, 0.545; 95% CI, 0.306-0.970, p=0.039) and MAFLD (OR, 0.375; 95% CI, 0.197-0.711, p=0.003) than did non-cancer subjects. There were no significant differences in the risks of metabolic syndrome and fatty liver diseases between non-OpGC and non-cancer subjects.
Conclusions
OpGC showed lower risks of metabolic syndrome, fatty liver by ultrasonography, and MAFLD than non-cancer subjects, but there were no significant differences in the risks between non-OpGC and non-cancer subjects. Further studies on metabolic syndrome and fatty liver diseases in gastric cancer survivors are warranted.

Keyword

Cancer survivors; Stomach neoplasms; Metabolic syndrome; Fatty liver

Figure

• 

  Fig. 1 Flowchart of study.

Reference

1. Hong S, Won YJ, Park YR, Jung KW, Kong HJ, Lee ES. Community of Population-Based Regional Cancer Registries. 2020; Cancer statistics in Korea: Incidence, mortality, survival, and prevalence in 2017. Cancer Res Treat. 52:335–350. DOI: 10.4143/crt.2020.206. PMID: 32178489. PMCID: PMC7176962.

2. Shin DW, Cho B, Kim SY, Jung JH, Park JH. 2013; Management of cancer survivors in clinical and public health perspectives: current status and future challenges in Korea. J Korean Med Sci. 28:651–657. DOI: 10.3346/jkms.2013.28.5.651. PMID: 23678254. PMCID: PMC3653075.

3. Leach CR, Weaver KE, Aziz NM, et al. 2015; The complex health profile of long-term cancer survivors: prevalence and predictors of comorbid conditions. J Cancer Surviv. 9:239–251. DOI: 10.1007/s11764-014-0403-1. PMID: 25319681.

4. Jung KW, Won YJ, Hong S, Kong HJ, Lee ES. 2020; Prediction of cancer incidence and mortality in Korea, 2020. Cancer Res Treat. 52:351–358. DOI: 10.4143/crt.2020.203. PMID: 32178488. PMCID: PMC7176954.

5. Shin JY, Choi YH, Song YM. 2015; Metabolic syndrome in Korean cancer survivors and family members: A study in a health promotion center. Nutr Cancer. 67:1075–1082. DOI: 10.1080/01635581.2015.1073752. PMID: 26317444.

6. Kim M, Kim IH, Lim MK, Kim Y, Park B. 2019; Increased prevalence of metabolic syndrome in adult cancer survivors: Asian first report in community setting. Cancer Epidemiol. 58:130–136. DOI: 10.1016/j.canep.2018.12.006. PMID: 30576983.

7. Brown JC, Harhay MO, Harhay MN. 2017; Nonalcoholic fatty liver disease and mortality among cancer survivors. Cancer Epidemiol. 48:104–109. DOI: 10.1016/j.canep.2017.04.007. PMID: 28460349. PMCID: PMC5549274.

8. Eslam M, Sanyal AJ, George J. International Consensus Panel. 2020; MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 158:1999–2014.e1. DOI: 10.1053/j.gastro.2019.11.312. PMID: 32044314.

9. Kunz PL, Gubens M, Fisher GA, Ford JM, Lichtensztajn DY, Clarke CA. 2012; Long-term survivors of gastric cancer: a California population-based study. J Clin Oncol. 30:3507–3515. DOI: 10.1200/JCO.2011.35.8028. PMID: 22949151.

10. Park W, Lee JK, Kim CR, Shin JY. 2015; Factors associated with fatigue in Korean gastric cancer survivors. Korean J Fam Med. 36:328–334. DOI: 10.4082/kjfm.2015.36.6.328. PMID: 26634101. PMCID: PMC4666870.

11. Lee JE, Shin DW, Lee H, et al. 2016; One-year experience managing a cancer survivorship clinic using a shared-care model for gastric cancer survivors in Korea. J Korean Med Sci. 31:859–865. DOI: 10.3346/jkms.2016.31.6.859. PMID: 27247493. PMCID: PMC4853663.

12. Kim M, Choi KS, Suh M, Jun JK, Chuck KW, Park B. 2018; Risky Lifestyle behaviors among gastric cancer survivors compared with matched non-cancer controls: Results from baseline result of community based cohort study. Cancer Res Treat. 50:738–747. DOI: 10.4143/crt.2017.129. PMID: 28745037. PMCID: PMC6056967.

13. Shim JY, Kang HT, Kim SY, et al. 2015; Clinical practice guideline of prevention and treatment for metabolic syndrome. Korean J Fam Pract. 5:375–420.

14. Mathiesen UL, Franzén LE, Aselius H, et al. 2002; Increased liver echogenicity at ultrasound examination reflects degree of steatosis but not of fibrosis in asymptomatic patients with mild/moderate abnormalities of liver transaminases. Dig Liver Dis. 34:516–522. DOI: 10.1016/S1590-8658(02)80111-6. PMID: 12236486.

15. Chiloiro M, Caruso MG, Cisternino AM, et al. 2013; Ultrasound evaluation and correlates of fatty liver disease: a population study in a Mediterranean area. Metab Syndr Relat Disord. 11:349–358. DOI: 10.1089/met.2012.0169. PMID: 23758075.

16. Eslam M, Newsome PN, Sarin SK, et al. 2020; A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 73:202–209. DOI: 10.1016/j.jhep.2020.03.039. PMID: 32278004.

17. Lee JY, Park NH, Song YS, et al. 2013; Prevalence of the metabolic syndrome and associated factors in korean cancer survivors. Asian Pac J Cancer Prev. 14:1773–1780. DOI: 10.7314/APJCP.2013.14.3.1773. PMID: 23679272.

18. Jung HS, Myung SK, Kim BS, Seo HG. 2012; Metabolic syndrome in adult cancer survivors: a meta-analysis. Diabetes Res Clin Pract. 95:275–282. DOI: 10.1016/j.diabres.2011.08.029. PMID: 22078073.

19. Nuver J, Smit AJ, Wolffenbuttel BH, et al. 2005; The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer. J Clin Oncol. 23:3718–3725. DOI: 10.1200/JCO.2005.02.176. PMID: 15738540.

20. Barnea D, Raghunathan N, Friedman DN, Tonorezos ES. 2015; Obesity and metabolic disease after childhood cancer. Oncology (Williston Park). 29:849–855.

21. Majhail NS, Flowers ME, Ness KK, et al. 2009; High prevalence of metabolic syndrome after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 43:49–54. DOI: 10.1038/bmt.2008.263. PMID: 18724397. PMCID: PMC2628412.

22. Annaloro C, Usardi P, Airaghi L, et al. 2008; Prevalence of metabolic syndrome in long-term survivors of hematopoietic stem cell transplantation. Bone Marrow Transplant. 41:797–804. DOI: 10.1038/sj.bmt.1705972. PMID: 18195686.

23. de Haas EC, Oosting SF, Lefrandt JD, Wolffenbuttel BH, Sleijfer DT, Gietema JA. 2010; The metabolic syndrome in cancer survivors. Lancet Oncol. 11:193–203. DOI: 10.1016/S1470-2045(09)70287-6. PMID: 20152771.

24. Lin XH, Huang KH, Chuang WH, et al. 2018; The long term effect of metabolic profile and microbiota status in early gastric cancer patients after subtotal gastrectomy. PLoS One. 13:e0206930. DOI: 10.1371/journal.pone.0206930. PMID: 30395589. PMCID: PMC6218198.

25. Batman B, Altun H, Simsek B, Aslan E, Namli Koc S. 2019; The effect of laparoscopic sleeve gastrectomy on nonalcoholic fatty liver disease. Surg Laparosc Endosc Percutan Tech. 29:509–512. DOI: 10.1097/SLE.0000000000000672. PMID: 31107849.

26. Cabré N, Luciano-Mateo F, Fernández-Arroyo S, et al. 2019; Laparoscopic sleeve gastrectomy reverses non-alcoholic fatty liver disease modulating oxidative stress and inflammation. Metabolism. 99:81–89. DOI: 10.1016/j.metabol.2019.07.002. PMID: 31279739.

27. Salman MA, El-Ghobary M, Soliman A, et al. 2020; Long-term changes in leptin, chemerin, and ghrelin levels following Roux-en-Y Gastric bypass and laparoscopic sleeve gastrectomy. Obes Surg. 30:1052–1060. DOI: 10.1007/s11695-019-04254-z. PMID: 31713147.

28. Cummings DE. 2006; Ghrelin and the short- and long-term regulation of appetite and body weight. Physiol Behav. 89:71–84. DOI: 10.1016/j.physbeh.2006.05.022. PMID: 16859720.

29. Klok MD, Jakobsdottir S, Drent ML. 2007; The role of leptin and ghrelin in the regulation of food intake and body weight in humans: a review. Obes Rev. 8:21–34. DOI: 10.1111/j.1467-789X.2006.00270.x. PMID: 17212793.

30. Fakhry TK, Mhaskar R, Schwitalla T, Muradova E, Gonzalvo JP, Murr MM. 2019; Bariatric surgery improves nonalcoholic fatty liver disease: a contemporary systematic review and meta-analysis. Surg Obes Relat Dis. 15:502–511. DOI: 10.1016/j.soard.2018.12.002. PMID: 30683512.

31. Jeong EH, Jun DW, Cho YK, et al. 2013; Regional prevalence of non-alcoholic fatty liver disease in Seoul and Gyeonggi-do, Korea. Clin Mol Hepatol. 19:266–272. DOI: 10.3350/cmh.2013.19.3.266. PMID: 24133664. PMCID: PMC3796676.

32. Kouzu K, Tsujimoto H, Nishikawa M, et al. 2020; Risk factors for nonalcoholic fatty liver disease after gastrectomy for gastric cancer. Gastric Cancer. 23:356–362. DOI: 10.1007/s10120-019-01009-8. PMID: 31555950.